NICE has released new guidance on the use of inclisiran (Leqvio) for lipid modification, published last October. You have probably already heard about this as it was widely reported in the news.
Why is inclisiran important for GPs?
It’s a new drug and is likely to be started and continued in primary care. It looks like it will start being widely used from 2022.
How does inclisiran work?
It is a small interfering ribonucleic acid (siRNA). It gets taken up into hepatocytes and causes increased recycling and expression of LDL-C receptors on the hepatocyte cell surface. This leads to increased LDL-C uptake and lower levels in the circulation.
